Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Therapy for bronchial asthma

Johnstone D, Dutton A The value of hyposensitization therapy for bronchial asthma in children A 14-year study. Pediatrics 1968 42 793-799. [Pg.41]

The first MDI products were developed by Riker Laboratories and marketed in 1956, using a newly patented design of metering valve. In most countries the MDI is now established as the principal dosage form of inhalation drug therapy for bronchial asthma and chronic obstructive pulmonary disease (COPD). Since its introduction, MDI technology has evolved steadily. However, with the phase-out in the commercial use of chlorofluorocarbon (CFC) propellants, which have been the mainstay of pharmaceutical MDIs, the pace of MDI technology development has accelerated with the transition to hydrofluorocarbon (HFC) propellants. ... [Pg.2269]

As a result of their ability to relax smooth muscle, calcium channel blocking drugs have numerous therapeutic applications, mainly in the treatment of cardiovascular disorders but possibly also in therapy for bronchial asthma, gastrointestinal muscle spasms and uterine disorders. The in vivo effects of the... [Pg.281]

Nelson HS. Adrenergic therapy for bronchial asthma. J Allergy Clin Immunol 1986 77 771-785. [Pg.226]

See other pages where Therapy for bronchial asthma is mentioned: [Pg.229]   
See also in sourсe #XX -- [ Pg.334 , Pg.335 , Pg.336 ]



SEARCH



Bronchial

Bronchial asthma,

For asthma

© 2024 chempedia.info